Company news
Resverlogix Corp. news in 2011
Resverlogix Corp.'s news releases, calls and decks from 2011, newest first.
Resverlogix Closes Equity Offering
November 29, 2011
Resverlogix Announces Full Enrollment of SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
November 28, 2011
Resverlogix Announces $17.5 million Equity Offering
November 23, 2011
Resverlogix Announces the Issuing of Patent Covering RVX-208
November 15, 2011
Resverlogix Commences Dosing in ASSURE a Phase 2b IVUS Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
November 2, 2011
Resverlogix Expands Phase 2b Program with the Commencement of Dosing in SUSTAIN
September 27, 2011
Resverlogix Activates Study Sites in ASSURE Phase 2b IVUS Trial for Atherosclerotic Plaque Regression
September 26, 2011
Resverlogix Presents Two Abstracts on Analysis of the Phase 2 ASSERT Clinical Trial at The ESC Congress 2011
September 1, 2011
Resverlogix Presents New Findings on RVX-208 at European Atherosclerosis Society
June 28, 2011
Resverlogix Announces New Data on Autoimmune Program featured at World Congress of Inflammation
June 27, 2011
Resverlogix Announces Dr. H. Bryan Brewer Joins Clinical Steering Committee
June 23, 2011
Resverlogix Launches Phase IIb ASSURE Trial for RVX-208 Cholesterol Transport Drug, Safety Data Completed and Filed
June 13, 2011
Investment Industry Regulatory Organization of Canada - Trade Resumption - Resverlogix Corp. - RVX
June 3, 2011
Resverlogix to Raise $12.6 Million
June 3, 2011
Investment Industry Regulatory Organization of Canada - Trading Halt - Resverlogix Corp. - RVX
June 3, 2011
Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's Disease
January 25, 2011